<DOC>
	<DOCNO>NCT00381602</DOCNO>
	<brief_summary>Malnutrition alter protein catabolism serious problem renal failure hemodialysis ( HD ) patient . The purpose study characterize safety GHRP-1/AG subject ESRD HD ; characterize pharmacodynamics ( PD ) GHRP-1/AG subject ESRD HD follow GH IGF-1 ; describe relationship GHRP-1 PD plasma concentration GHRP-1 des-Ala-GHRP-1 ; evaluate preliminary efficacy GHRP-1/AG nutritional status subject ESRD HD use subjective global assessment malnutrition inflammation score ( MIS ) change caloric intake .</brief_summary>
	<brief_title>A Phase II , Randomized , Cross-Over , Vehicle-Controlled , Double-Blind , Multicenter Study Safety , Pharmacodynamics , Preliminary Efficacy GHRP-1/AG Subjects With ESRD Hemodialysis</brief_title>
	<detailed_description>This randomize , cross-over , double-blind , vehicle-controlled study . Subjects receive single subcutaneous injection active GHRP-1/AG study treatment vehicle control ( ATRIGEL delivery system ) randomize sequence . Each injection follow 4-week period treatment exposure 2-week period washout/follow-up . Treatments administer 2nd dialysis day 3x/week dialysis schedule . The total duration study participation 12 week . Safety follow throughtout study vital sign , electrocardiogram , clinical chemistry hematology parameter , endocrine parameter , adverse event , concomitant medication . PD effect GHRP-1/AG evaluate measure GH , ICF-1 , IGF-BP3 , prolactin , cortisol . Efficacy evaluate throughout study MIS , caloric intake , nPCR , dry weight , BMI , albumin , BUN , creatinine , calcium , potassium , HGB , HCT , CBC .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Subjects ESRD HD least 3 month urea reduction rate ( URR ) least 65 % . Subjects 18 70 year age . Subjects body mass index ( BMI ) less 30 , albumin great 3.3 g/dL , MIS 5 10 ( inclusive ) . Subjects diabetes currently take insulin . Subjects history current significant central nervous system ( CNS ) disorder . Subjects active infection baseline . Subjects active unstable cardiac arterial disease . Subjects uncontrolled tertiary hyperparathyroid condition . Subjects anemia . Subjects history hepatitis current liver disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>End stage renal disease</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Malnutrition</keyword>
	<keyword>End stage renal disease ( ESRD )</keyword>
</DOC>